Session » Metabolic and Crystal Arthropathies Poster II

Date: Tuesday, November 7, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2071

A Novel Selective URAT1 Inhibitor, Tei-a, with Potent Uricosuric Property

9:00AM-11:00AM: Abstract Number: 2072

A Pharmacokinetic and Pharmacodynamic Evaluation of URC102, a Potent and Selective Inhibitor of URAT1, after Single and Multiple Oral Administrations in Healthy Volunteers

9:00AM-11:00AM: Abstract Number: 2074

A Series of Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Studies to Evaluate the Efficacy, Safety, and Dose-Response Relationship of Orally Administered URC102, a Novel URAT1 Inhibitor, in Korean Patients with Gout

9:00AM-11:00AM: Abstract Number: 2058

A Study on Febuxostat Prescribing Practices for Patients with Chronic Gout Previously Managed with Allopurinol at the Veterans Affairs Puget Sound

9:00AM-11:00AM: Abstract Number: 2087

Allelic Variants of ABCG2 and Gout Risk

9:00AM-11:00AM: Abstract Number: 2059

Allopurinol Dose-Titration Patterns Relative to Serum Uric Acid Levels in Gout Patients: US Electronic Health Record Data

9:00AM-11:00AM: Abstract Number: 2052

Apply Musculoskeletal Ultrasonography to Predict Chronic Gouty Arthritis in Patients with Chronic Kidney Diseases

9:00AM-11:00AM: Abstract Number: 2089

Arhalofenate Acid Inhibits Urate Crystal-Induced Inflammatory Responses through Activation of AMP-Activated Protein Kinase (AMPK) Signaling

9:00AM-11:00AM: Abstract Number: 2086

Calcium Pyrophosphate Crystal Size, Shape and Appearance Variability

9:00AM-11:00AM: Abstract Number: 2082

Clinical Presentation, Management, and Prognosis of Pseudogout in Prosthetic Joint Implant Patients: A Retrospective Study

9:00AM-11:00AM: Abstract Number: 2088

Clinical Significance of Urate Deposition in Tendon: A Dual-Energy CT Study

9:00AM-11:00AM: Abstract Number: 2076

Comparative Effectiveness of Allopurinol Versus Febuxostat in Preventing Incident Dementia in the Elderly

9:00AM-11:00AM: Abstract Number: 2053

Computed Tomography Dependent Diagnosis of Crowned Dens Syndrome; A Cervical Manifestation of Patients with Calcium Pyrophosphate Dihydrate Crystal Deposition Disease

9:00AM-11:00AM: Abstract Number: 2070

Evidence-Based Development of Criteria for Complete Response in Patients with Chronic Refractory Gout

9:00AM-11:00AM: Abstract Number: 2062

Flow-Mediated Dilation As a Marker of Endothelial Dysfunction in Gout

9:00AM-11:00AM: Abstract Number: 2069

Gout Is More Frequent in Sickle Cell Disease Than the General Population

9:00AM-11:00AM: Abstract Number: 2065

Higher Urate Volume Measured By Dual Energy Computed Tomography Is Associated with Unfavourable Cardiovascular Risks in Patients with Gout

9:00AM-11:00AM: Abstract Number: 2078

Hypersensitivity Reactions with Allopurinol and Febuxostat in Adults 65 Years or Older: A Study Using the Medicare Claims Data

9:00AM-11:00AM: Abstract Number: 2057

Identification of Urate Deposits in Patients with Asymptomatic Hyperuricemia Using a Dual-Energy CT Scan

9:00AM-11:00AM: Abstract Number: 2091

Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies

9:00AM-11:00AM: Abstract Number: 2066

Mediation Analysis to Understand Genetic Relationships between Habitual Coffee Intake and Gout

9:00AM-11:00AM: Abstract Number: 2055

Omeract Ultrasonographic Criteria for the Diagnosis of Calcium Pyrophosphate Deposition Disease at the Metacarpal-Phalangeal, Wrist, Acromion-Clavicular and Hip Joints: An Inter-Observer and Intra-Observer Reliability Study

9:00AM-11:00AM: Abstract Number: 2084

Patients with Early Onset Gout Develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions

9:00AM-11:00AM: Abstract Number: 2056

Performance and Validity of Musculoskeletal Ultrasound in the Assessment of Synovial Inflammation in Experimental Acute Gout

9:00AM-11:00AM: Abstract Number: 2061

Population-Specific Factors Associated with Fractional Excretion of Uric Acid

9:00AM-11:00AM: Abstract Number: 2073

Predictors for Clinically Diagnosed Gout – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden

9:00AM-11:00AM: Abstract Number: 2068

Previous Prescription of Allopurinol Reduces the Risk of Nsaids-Related Acute Kidney Injury in Patients with Gout

9:00AM-11:00AM: Abstract Number: 2060

Pseudogout Among Patients Fulfilling a Billing Code Algorithm for Calcium Pyrophosphate Deposition Disease (CPPD)

9:00AM-11:00AM: Abstract Number: 2054

Rapid Tophus Resolution in Chronic Refractory Gout Patients Treated with Pegloticase

9:00AM-11:00AM: Abstract Number: 2063

Relation of Serum Urate and Gout Duration to Tophi, Urate Deposition, and Inflammation

9:00AM-11:00AM: Abstract Number: 2085

Relationship between Gout and Asthma: A National Database Analysis

9:00AM-11:00AM: Abstract Number: 2079

Rotator Cuff Calcific Tendinopathy: Chondrocyte-like Cells Surrounding Calcific Deposits Express TNAP and ENPP1, Two Key Enzymes of the Mineralization Process.

9:00AM-11:00AM: Abstract Number: 2080

Serum Uric Acid and Incident Dementia: A Population Based Study

9:00AM-11:00AM: Abstract Number: 2077

Statin Use and Mortality in Gout: A General Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 2081

Synovial Fluid Leukocyte Count and Its Association with Crystal Deposition in Asymptomatic Hyperuricemia

9:00AM-11:00AM: Abstract Number: 2075

The Effect of Uric Acid Lowering Treatment on the Microbiome in Gout Patients

9:00AM-11:00AM: Abstract Number: 2083

The Inflammation Induced By Four Types of Calcium Pyrophosphate Crystals Depends on Their Capacity to Stimulate NF-κb and MAPK Pathways

9:00AM-11:00AM: Abstract Number: 2064

The Nomenclature of Gout: A Content Analysis of Contemporary Medical Journals

9:00AM-11:00AM: Abstract Number: 2067

Treatment with Pegloticase Significantly Decreases Mean Arterial Blood Pressure in Patients with Chronic Gout

9:00AM-11:00AM: Abstract Number: 2090

Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with Veterans Affairs Medical Center

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].